Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Nantahala Capital Management LLC

Key Points

• Nantahala Capital Management LLC increased its stake in Amneal Pharmaceuticals by 3.9%, now owning 3,808,561 shares, which represents approximately 1.3% of its investment portfolio.
• Amneal Pharmaceuticals reported a quarterly EPS of $0.23, exceeding the consensus estimate by $0.06, and has set its FY 2025 guidance at 0.700-0.750 EPS.
• Multiple analysts have a "buy" rating on AMRX, with Goldman Sachs setting a price target of $12.00 and the average target price currently at $11.60.

Nantahala Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,808,561 shares of the company's stock after acquiring an additional 143,032 shares during the period. Amneal Pharmaceuticals comprises approximately 1.3% of Nantahala Capital Management LLC's investment portfolio, making the stock its 9th biggest holding. Nantahala Capital Management LLC owned approximately 1.23% of Amneal Pharmaceuticals worth $31,916,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Janney Montgomery Scott LLC raised its stake in shares of Amneal Pharmaceuticals by 26.9% during the first quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock valued at $162,000 after acquiring an additional 4,100 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Amneal Pharmaceuticals by 53.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock valued at $508,000 after acquiring an additional 21,079 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Amneal Pharmaceuticals by 45.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock worth $2,522,000 after buying an additional 99,866 shares in the last quarter. California State Teachers Retirement System raised its stake in Amneal Pharmaceuticals by 10.3% in the fourth quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after buying an additional 12,282 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Amneal Pharmaceuticals by 209.2% in the fourth quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after buying an additional 113,796 shares in the last quarter. Institutional investors own 31.82% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AMRX. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group began coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $11.60.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director John Kiely sold 32,000 shares of the company's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the sale, the director directly owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. This represents a 12.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jason B. Daly sold 22,000 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the sale, the executive vice president directly owned 10,606 shares in the company, valued at approximately $95,984.30. The trade was a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 609,206 shares of company stock valued at $5,700,625 in the last three months. Company insiders own 17.45% of the company's stock.

Amneal Pharmaceuticals Stock Up 0.1%

Shares of AMRX traded up $0.01 during trading hours on Thursday, reaching $9.55. 1,622,592 shares of the company traded hands, compared to its average volume of 1,675,065. The stock has a market capitalization of $3.00 billion, a P/E ratio of 955.96 and a beta of 1.19. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $9.79. The business has a fifty day moving average price of $8.64 and a 200-day moving average price of $8.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.